Pharmaceutical

Apollo Therapeutics secures $226.5m to advance pipeline programmes

Portfolio biopharmaceutical company Apollo Therapeutics has secured $226.5m in a Series C funding round to advance its pipeline of programmes.

Sep 7, 2023 - 20:00
Apollo Therapeutics secures $226.5m to advance pipeline programmes
Portfolio biopharmaceutical company Apollo Therapeutics has secured $226.5m in a Series C funding round to advance its pipeline of programmes.
Read the original article

Tags:

Previous Article

Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 

Next Article

Signal: Nimbus raises $210m to foster drug discovery plans

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Injectables manufacturing ushers in a new era of accessibility

Injectables manufacturing ushers in a new era of access...

Nov 5, 2024

STAT+: Gilead sours on the ‘don’t eat me’ business

STAT+: Gilead sours on the ‘don’t eat me’ business

Feb 11, 2024

Ketamine is comparable to ECT for patients with treatment-resistant depression, study shows

Ketamine is comparable to ECT for patients with treatme...

May 25, 2023